Dextroamphetamine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:596899008
Inn:dexamfetamine
Width:210
Imagel:D-Amphetamine-3D-balls.png
Imager:Amphetamine-3d-CPK.png
Tradename:Dexedrine, others
Dailymedid:Dextroamphetamine
Pregnancy Au:B3
Dependency Liability:Moderate[1] [2] - high[3] [4]
Addiction Liability:Moderate - high
Routes Of Administration:By mouth, transdermal
Atc Prefix:N06
Atc Suffix:BA02
Legal Au:S8
Legal Au Comment:[5] [6]
Legal Br:A3
Legal Br Comment:[7]
Legal Ca:Rx-only
Legal Ca Comment:/Schedule G (CDSA I)[8]
Legal De:Anlage III
Legal Uk:Class B
Legal Us:Schedule II
Legal Us Comment:[9] [10]
Legal Eu:Rx-only
Legal Eu Comment:[11]
Legal Un:P II
Legal Status:SE: Förteckning II
Bioavailability:Oral: ~90%
Protein Bound:15–40%
Metabolism:CYP2D6, DBH,[12] FMO3
Onset: dosing: 0.5–1.5 hours[13]
Quote:Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.[14]
dosing: 1.5–2 hours[15] [16]
Elimination Half-Life:9–11 hours[17]
pH-dependent: 7–34 hours
Duration Of Action: dosing: 3–6 hours[18]
dosing: 8–12 hours[19]
Excretion:Kidney (45%);[20] urinary pH-dependent
Cas Number:51-64-9
Pubchem:5826
Iuphar Ligand:2147
Drugbank:DB01576
Chemspiderid:5621
Unii:TZ47U051FI
Kegg:D03740
Chebi:4469
Chembl:612
Synonyms:d-Amphetamine, (S)-Amphetamine, S(+)-Amphetamine
Iupac Name:(2S)-1-Phenylpropan-2-amine
C:9
H:13
N:1
Chirality:Dextrorotatory enantiomer
Smiles:C[C@@H](Cc1ccccc1)N
Stdinchi:InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
Stdinchikey:KWTSXDURSIMDCE-QMMMGPOBSA-N
Density:0.913
Boiling Point:201.5
Solubility:20

Dextroamphetamine (INN:dexamfetamine) is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used as an athletic performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.

The amphetamine molecule exists as two enantiomers, levoamphetamine and dextroamphetamine. Dextroamphetamine is the dextrorotatory, or 'right-handed', enantiomer and exhibits more pronounced effects on the central nervous system than levoamphetamine. Pharmaceutical dextroamphetamine sulfate is available as both a brand name and generic drug in a variety of dosage forms. Dextroamphetamine is sometimes prescribed as the inactive prodrug lisdexamfetamine dimesylate, which is converted into dextroamphetamine after absorption.

Dextroamphetamine, like other amphetamines, elicits its stimulating effects via several distinct actions: it inhibits or reverses the transporter proteins for the monoamine neurotransmitters (namely the serotonin, norepinephrine and dopamine transporters) either via trace amine-associated receptor 1 (TAAR1) or in a TAAR1 independent fashion when there are high cytosolic concentrations of the monoamine neurotransmitters and it releases these neurotransmitters from synaptic vesicles via vesicular monoamine transporter 2. It also shares many chemical and pharmacological properties with human trace amines, particularly phenethylamine and, the latter being an isomer of amphetamine produced within the human body. It is available as a generic medication.[21] In 2021, it was the 17th most commonly prescribed medication in the United States, with more than 30.3million prescriptions.[22] [23]

Uses

Medical

Dextroamphetamine is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy (a sleep disorder), and is sometimes prescribed for depression and obesity.

Recreational

Dextroamphetamine is also used recreationally as a euphoriant and aphrodisiac, and like other amphetamines is used as a club drug for its energetic and euphoric high. Dextroamphetamine is considered to have a high potential for misuse in a recreational manner since individuals typically report feeling euphoric, more alert, and more energetic after taking the drug.[24] [25] Dextroamphetamine's dopaminergic (rewarding) properties affect the mesocorticolimbic circuit; a group of neural structures responsible for incentive salience (i.e., "wanting"; desire or craving for a reward and motivation), positive reinforcement and positively-valenced emotions, particularly ones involving pleasure.[26] Large recreational doses of dextroamphetamine may produce symptoms of dextroamphetamine overdose. Recreational users sometimes open dexedrine capsules and crush the contents in order to insufflate (snort) it or subsequently dissolve it in water and inject it.[27] Immediate-release formulations have higher potential for abuse via insufflation (snorting) or intravenous injection due to a more favorable pharmacokinetic profile and easy crushability (especially tablets).[28] [29]

The reason for using crushed spansules for insufflation and injection methods is evidently due to the "instant-release" forms of the drug seen in tablet preparations often containing a sizable amount of inactive binders and fillers alongside the active d-amphetamine, such as dextrose.[30] Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels. Chronic overuse of dextroamphetamine can lead to severe drug dependence, resulting in withdrawal symptoms when drug use stops.

Interactions

Many types of substances are known to interact with amphetamine, resulting in altered drug action or metabolism of amphetamine, the interacting substance, or both. Inhibitors of the enzymes that metabolize amphetamine (e.g., CYP2D6 and FMO3) will prolong its elimination half-life, meaning that its effects will last longer.[31] [32] Amphetamine also interacts with, particularly monoamine oxidase A inhibitors, since both MAOIs and amphetamine increase plasma catecholamines (i.e., norepinephrine and dopamine); therefore, concurrent use of both is dangerous. Amphetamine modulates the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of sedatives and depressants and increase the effects of stimulants and antidepressants. Amphetamine may also decrease the effects of antihypertensives and antipsychotics due to its effects on blood pressure and dopamine respectively. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD.[33]

Pharmacology

Pharmacodynamics

Amphetamine and its enantiomers have been identified as potent full agonists of trace amine-associated receptor 1 (TAAR1), a GPCR, discovered in 2001, that is important for regulation of monoaminergic systems in the brain.[34] Activation of TAAR1 increases cAMP production via adenylyl cyclase activation and inhibits the function of the dopamine transporter, norepinephrine transporter, and serotonin transporter, as well as inducing the release of these monoamine neurotransmitters (effluxion).[35] [36] Amphetamine enantiomers are also substrates for a specific neuronal synaptic vesicle uptake transporter called VMAT2. When amphetamine is taken up by VMAT2, the vesicle releases (effluxes) dopamine, norepinephrine, and serotonin, among other monoamines, into the cytosol in exchange.[37]

Dextroamphetamine (the dextrorotary enantiomer) and levoamphetamine (the levorotary enantiomer) have identical pharmacodynamics, but their binding affinities to their biomolecular targets vary.[38] Dextroamphetamine is a more potent agonist of TAAR1 than levoamphetamine. Consequently, dextroamphetamine produces roughly three to four times more central nervous system (CNS) stimulation than levoamphetamine;[39] however, levoamphetamine has slightly greater cardiovascular and peripheral effects.

Pharmacokinetics

History, society, and culture

See main article: History and culture of amphetamines. Racemic amphetamine was first synthesized under the chemical name "phenylisopropylamine" in Berlin, 1887 by the Romanian chemist Lazăr Edeleanu. It was not widely marketed until 1932, when the pharmaceutical company Smith, Kline & French (now known as GlaxoSmithKline) introduced it in the form of the Benzedrine inhaler for use as a bronchodilator. Notably, the amphetamine contained in the Benzedrine inhaler was the liquid free-base,[40] not a chloride or sulfate salt.

Three years later, in 1935, the medical community became aware of the stimulant properties of amphetamine, specifically the dextroamphetamine isomer, and in 1937 Smith, Kline, and French introduced tablets under the brand name Dexedrine.[41] In the United States, Dexedrine was approved to treat narcolepsy and attention disorders. In Canada indications once included epilepsy and parkinsonism.[42] Dextroamphetamine was marketed in various other forms in the following decades, primarily by Smith, Kline, and French, such as several combination medications including a mixture of dextroamphetamine and amobarbital (a barbiturate) sold under the tradename Dexamyl and, in the 1950s, an extended release capsule (the "Spansule").[43] Preparations containing dextroamphetamine were also used in World War II as a treatment against fatigue.[44]

It quickly became apparent that dextroamphetamine and other amphetamines had a high potential for misuse, although they were not heavily controlled until 1970, when the Comprehensive Drug Abuse Prevention and Control Act was passed by the United States Congress. Dextroamphetamine, along with other sympathomimetics, was eventually classified as Schedule II, the most restrictive category possible for a drug with a government-sanctioned, recognized medical use.[45] Internationally, it has been available under the names AmfeDyn (Italy), Curban (US), Obetrol (Switzerland), Simpamina (Italy), Dexedrine/GSK (US & Canada), Dexedrine/UCB (United Kingdom), Dextropa (Portugal), and Stild (Spain).[46] It became popular on the mod scene in England in the early 1960s, and carried through to the Northern Soul scene in the north of England to the end of the 1970s.

In October 2010, GlaxoSmithKline sold the rights for Dexedrine Spansule to Amedra Pharmaceuticals (a subsidiary of CorePharma).[47]

The U.S. Air Force uses dextroamphetamine as one of its "go pills", given to pilots on long missions to help them remain focused and alert. Conversely, "no-go pills" are used after the mission is completed, to combat the effects of the mission and "go-pills".[48] [49] [50] The Tarnak Farm incident was linked by media reports to the use of this drug on long term fatigued pilots. The military did not accept this explanation, citing the lack of similar incidents. Newer stimulant medications or awakeness promoting agents with different side effect profiles, such as modafinil, are being investigated and sometimes issued for this reason.

Formulations

Brand
name! scope="col"
United States
Adopted Name		(D:L) ratioDosage
form		Marketing
start date		Sources
Adderall Mixed amphetamine salts 3:1 (salts)tablet 1996
Adderall XR Mixed amphetamine salts 3:1 (salts) capsule 2001 [51] [52]
Mydayis Mixed amphetamine salts 3:1 (salts) capsule 2017 [53]
Adzenys XR-ODT amphetamine 3:1 (base) 2016 [54] [55]
Dyanavel XR amphetamine 3.2:1 (base) suspension 2015 [56]
Evekeo amphetamine sulfate 1:1 (salts) tablet 2012 Contraindications --> [57]
Dexedrine dextroamphetamine sulfate 1:0 (salts) capsule 1976
Zenzedi dextroamphetamine sulfate 1:0 (salts) tablet 2013
Vyvanse lisdexamfetamine dimesylate 1:0 (prodrug) capsule 2007
tablet
Xelstrym dextroamphetamine 1:0 (base) patch 2022

Transdermal Dextroamphetamine Patches

Dextroamphetamine is available as a transdermal patch containing dextroamphetamine base under the brand name Xelstrym.

Dextroamphetamine sulfate

In the United States, immediate release (IR) formulations of dextroamphetamine sulfate are available generically as 5 mg and 10 mg tablets, marketed by Barr (Teva Pharmaceutical Industries), Mallinckrodt Pharmaceuticals, Wilshire Pharmaceuticals, Aurobindo Pharmaceutical USA and CorePharma. Previous IR tablets sold under the brand names Dexedrine and Dextrostat have been discontinued but in 2015, IR tablets became available by the brand name Zenzedi, offered as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 30 mg tablets.[58] Dextroamphetamine sulfate is also available as a controlled-release (CR) capsule preparation in strengths of 5 mg, 10 mg, and 15 mg under the brand name Dexedrine Spansule, with generic versions marketed by Barr and Mallinckrodt. A bubblegum flavored oral solution is available under the brand name ProCentra, manufactured by FSC Pediatrics, which is designed to be an easier method of administration in children who have difficulty swallowing tablets, each 5 mL contains 5 mg dextroamphetamine.[59] The conversion rate between dextroamphetamine sulfate to amphetamine free base is .728.[60]

In Australia, dexamfetamine is available in bottles of 100 instant release 5 mg tablets as a generic drug[61] or slow release dextroamphetamine preparations may be compounded by individual chemists.[62] In the United Kingdom, it is available in 5 mg instant release sulfate tablets under the generic name dexamfetamine sulfate as well as 10 mg and 20 mg strength tablets under the brand name Amfexa. It is also available in generic dexamfetamine sulfate 5 mg/ml oral sugar-free syrup.[63] The brand name Dexedrine was available in the United Kingdom prior to UCB Pharma disinvesting the product to another pharmaceutical company (Auden Mckenzie).[64]

Lisdexamfetamine

See main article: Lisdexamfetamine. Dextroamphetamine is the active metabolite of the prodrug lisdexamfetamine (L-lysine-dextroamphetamine), available by the brand name Vyvanse (Elvanse in the European market) (Venvanse in the Brazil market) (lisdexamfetamine dimesylate). Dextroamphetamine is liberated from lisdexamfetamine enzymatically following contact with red blood cells. The conversion is rate-limited by the enzyme, which prevents high blood concentrations of dextroamphetamine and reduces lisdexamfetamine's drug liking and abuse potential at clinical doses.[65] [66] Vyvanse is marketed as once-a-day dosing as it provides a slow release of dextroamphetamine into the body. Vyvanse is available as capsules, and chewable tablets, and in seven strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The conversion rate between lisdexamfetamine dimesylate (Vyvanse) to dextroamphetamine base is 29.5%.[67] [68] [69]

Adderall

See main article: Adderall. Another pharmaceutical that contains dextroamphetamine is commonly known by the brand name Adderall. It is available as immediate release (IR) tablets and extended release (XR) capsules. Adderall contains equal amounts of four amphetamine salts:

Adderall has a total amphetamine base equivalence of 63%. While the enantiomer ratio by dextroamphetamine salts to levoamphetamine salts is 3:1, the amphetamine base content is 75.9% dextroamphetamine, 24.1% levoamphetamine.

Notes

Image legend

External links

Notes and References

  1. Vitiello B . Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function . Child and Adolescent Psychiatric Clinics of North America . 17 . 2 . 459–74, xi . April 2008 . 18295156 . 2408826 . 10.1016/j.chc.2007.11.010 .
  2. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E . European guidelines on managing adverse effects of medication for ADHD . European Child & Adolescent Psychiatry . 20 . 1 . 17–37 . January 2011 . 21042924 . 3012210 . 10.1007/s00787-010-0140-6 . 1435-165X .
  3. Kociancic T, Reed MD, Findling RL . Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children . Expert Opinion on Drug Safety . 3 . 2 . 93–100 . March 2004 . 15006715 . 10.1517/14740338.3.2.93 . 31114829 . 1744-764X .
  4. Clemow DB, Walker DJ . The potential for misuse and abuse of medications in ADHD: a review . Postgraduate Medicine . 126 . 5 . 64–81 . September 2014 . 25295651 . 10.3810/pgm.2014.09.2801 . 207580823 . 1941-9260 .
  5. Web site: Therapeutic Goods (Poisons Standard—February 2023) Instrument 2022 . Australian Government Federal Register of Legislation . 26 September 2022 . 9 January 2023.
  6. Web site: Fuller K . ADHD Stimulant Prescribing Regulations & Authorities in Australia & New Zealand . AADPA . 20 February 2022 . 9 January 2023.
  7. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  8. Web site: Product monograph brand safety updates . . 6 June 2024 . 8 June 2024.
  9. Web site: Dexedrine spansule- dextroamphetamine sulfate capsule, extended release . DailyMed . 10 January 2022 . 28 March 2022.
  10. Web site: Xelstrym- dextroamphetamine patch, extended release . DailyMed . 6 January 2023 . 21 January 2023.
  11. Web site: List of nationally authorised medicinal products : Active substance(s): dexamfetamine : Procedure No. PSUSA/00000986/202109. Ema.europa.eu. 5 June 2022.
  12. Book: Foye's Principles of Medicinal Chemistry . 2013 . Wolters Kluwer Health/Lippincott Williams & Wilkins . Philadelphia . 978-1-60913-345-0 . 648 . Lemke TL, Williams DA, Roche VF, Zito W . 7th . Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine..
  13. Book: Primary Care Pediatrics. Lippincott Williams & Wilkins. 1 January 2001. 978-0-7817-2008-3. Green-Hernandez C, Singleton JK, Aronzon DZ . 243.
  14. Web site: Dexedrine, ProCentra(dextroamphetamine) dosing, indications, interactions, adverse effects, and more. reference.medscape.com. 4 October 2015. Onset of action: 1–1.5 hr.
  15. Book: Millichap JG . Millichap JG . Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD . 2010 . Springer . New York, USA . 978-1-4419-1396-8 . 112 . 2nd . Chapter 9: Medications for ADHD .
    Table 9.2 Dextroamphetamine formulations of stimulant medication
    Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...
    Adderall [Peak:2–3 h] [Duration:5–7 h]
    Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...
    Adderall XR [Peak:7–8 h] [Duration:12 h]
    Vyvanse [Peak:3–4 h] [Duration:12 h].
  16. Brams M, Mao AR, Doyle RL . Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder . Postgrad. Med. . 120 . 3 . 69–88 . September 2008 . 18824827 . 10.3810/pgm.2008.09.1909 . 31791162 . Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose.
  17. Web site: Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet . DailyMed . 27 February 2022 . 21 January 2023.
  18. Mignot EJ . A practical guide to the therapy of narcolepsy and hypersomnia syndromes . Neurotherapeutics . 9 . 4 . 739–752 . October 2012 . 23065655 . 3480574 . 10.1007/s13311-012-0150-9.
  19. Book: Stahl SM . Prescriber's Guide: Stahl's Essential Psychopharmacology . March 2017 . Cambridge University Press . Cambridge, United Kingdom . 978-1-108-22874-9 . 39–44 . 6th . https://books.google.com/books?id=9hssDwAAQBAJ&pg=PA39 . Amphetamine (D) . 8 August 2017.
  20. Web site: dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]]. Shire US Inc.. DailyMed. August 2006. 8 November 2013. Wayne, PA.
  21. Web site: Dextroamphetamine Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 2 February 2019 . en . 3 February 2019 . https://web.archive.org/web/20190203030724/https://www.drugs.com/monograph/dextroamphetamine.html . live .
  22. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  23. Web site: Dextroamphetamine; Dextroamphetamine Saccharate; Amphetamine; Amphetamine Aspartate - Drug Usage Statistics . ClinCalc . 14 January 2024.
  24. Web site: Commonly Abused Prescription Drugs Chart . National Institute on Drug Abuse. 7 May 2012.
  25. Web site: Stimulant ADHD Medications – Methylphenidate and Amphetamines . National Institute on Drug Abuse . 7 May 2012 . 2 May 2012 . https://web.archive.org/web/20120502072325/http://www.drugabuse.gov/publications/infofacts/stimulant-adhd-medications-methylphenidate-amphetamines . dead .
  26. Schultz W . 2015 . Neuronal reward and decision signals: from theories to data . Physiological Reviews . 95 . 3 . 853–951 . 26109341 . 4491543 . 10.1152/physrev.00023.2014 . Rewards in operant conditioning are positive reinforcers. ... Operant behavior gives a good definition for rewards. Anything that makes an individual come back for more is a positive reinforcer and therefore a reward. Although it provides a good definition, positive reinforcement is only one of several reward functions. ... Rewards are attractive. They are motivating and make us exert an effort. ... Rewards induce approach behavior, also called appetitive or preparatory behavior, sexual behavior, and consummatory behavior. ... Thus any stimulus, object, event, activity, or situation that has the potential to make us approach and consume it is by definition a reward. ... Rewarding stimuli, objects, events, situations, and activities consist of several major components. First, rewards have basic sensory components (visual, auditory, somatosensory, gustatory, and olfactory) ... Second, rewards are salient and thus elicit attention, which are manifested as orienting responses. The salience of rewards derives from three principal factors, namely, their physical intensity and impact (physical salience), their novelty and surprise (novelty/surprise salience), and their general motivational impact shared with punishers (motivational salience). A separate form not included in this scheme, incentive salience, primarily addresses dopamine function in addiction and refers only to approach behavior (as opposed to learning) ... Third, rewards have a value component that determines the positively motivating effects of rewards and is not contained in, nor explained by, the sensory and attentional components. This component reflects behavioral preferences and thus is subjective and only partially determined by physical parameters. Only this component constitutes what we understand as a reward. It mediates the specific behavioral reinforcing, approach generating, and emotional effects of rewards that are crucial for the organism's survival and reproduction, whereas all other components are only supportive of these functions. ... Rewards can also be intrinsic to behavior. They contrast with extrinsic rewards that provide motivation for behavior and constitute the essence of operant behavior in laboratory tests. Intrinsic rewards are activities that are pleasurable on their own and are undertaken for their own sake, without being the means for getting extrinsic rewards. ... Intrinsic rewards are genuine rewards in their own right, as they induce learning, approach, and pleasure, like perfectioning, playing, and enjoying the piano. Although they can serve to condition higher order rewards, they are not conditioned, higher order rewards, as attaining their reward properties does not require pairing with an unconditioned reward. ... These emotions are also called liking (for pleasure) and wanting (for desire) in addiction research and strongly support the learning and approach generating functions of reward..
  27. Web site: National Institute on Drug Abuse. 2009. Stimulant ADHD Medications – Methylphenidate and Amphetamines. National Institute on Drug Abuse. 27 February 2013.
  28. Book: Canadian ADHD Practice Guidelines . 2018 . Canadian ADHD Resource Alliance . 67 . Fourth . 2 May 2023 . 2 May 2023 . https://web.archive.org/web/20230502204112/https://www.caddra.ca/wp-content/uploads/CADDRA-Guidelines-4th-Edition_-Feb2018.pdf . dead .
  29. Bright GM . Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey . Medscape Journal of Medicine . 10 . 5 . 111 . May 2008 . 18596945 . 2438483 .
  30. Childs E, de Wit H . Contextual conditioning enhances the psychostimulant and incentive properties of d-amphetamine in humans . Addiction Biology . November 2013 . 18 . 6 . 985–992 . 22129527 . 4242554 . 10.1111/j.1369-1600.2011.00416.x .
  31. Web site: Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet . DailyMed . 27 February 2022 . 28 March 2022.
  32. Web site: Adderall XR- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release . DailyMed . 3 March 2022 . 28 March 2022.
  33. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M . Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses . J. Am. Acad. Child Adolesc. Psychiatry . 51 . 10 . 1003–1019.e20 . October 2012 . 23021477 . 10.1016/j.jaac.2012.08.015.
  34. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK . Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor . Molecular Pharmacology . 60 . 6 . 1181–1188 . December 2001 . 11723224 . 10.1124/mol.60.6.1181 . 14140873 .
  35. Miller GM . The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity . Journal of Neurochemistry . 116 . 2 . 164–176 . January 2011 . 21073468 . 3005101 . 10.1111/j.1471-4159.2010.07109.x .
  36. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C . Trace amines: identification of a family of mammalian G protein-coupled receptors . Proceedings of the National Academy of Sciences of the United States of America . 98 . 16 . 8966–8971 . July 2001 . 11459929 . 55357 . 10.1073/pnas.151105198 . free . 2001PNAS...98.8966B .
  37. Eiden LE, Weihe E . VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse . Annals of the New York Academy of Sciences . 1216 . 1 . 86–98 . January 2011 . 21272013 . 4183197 . 10.1111/j.1749-6632.2010.05906.x . 2011NYASA1216...86E .
  38. Book: Brunton LL, Chabner BA, Knollmann BC . Goodman & Gilman's Pharmacological Basis of Therapeutics . 2010 . McGraw-Hill . New York . 978-0-07-162442-8 . Westfall DP, Westfall TC . Miscellaneous Sympathomimetic Agonists . http://www.accessmedicine.com/content.aspx?aID=16661601 . 12th .
  39. Lewin AH, Miller GM, Gilmour B . Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class . Bioorg. Med. Chem. . 19 . 23 . 7044–7048 . December 2011 . 22037049 . 3236098 . 10.1016/j.bmc.2011.10.007 .
  40. Free-base form amphetamine is a volatile oil, hence the efficacy of the inhalers.
  41. Web site: Dexedrine. Medic8. 27 November 2013. dead. https://web.archive.org/web/20091219120223/http://www.medic8.com/medicines/Dexedrine.html. 19 December 2009.
  42. Web site: Dextroamphetamine [monograph]]. Internet Mental Health. https://web.archive.org/web/20060427084347/http://www.mentalhealth.com/drug/p30-d04.html. 6 September 2015. 27 April 2006.
  43. Web site: Information on Dexedrine: A Quick Review Weitz & Luxenberg . Weitzlux.com . 31 August 2013 . 5 January 2017.
  44. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present—a pharmacological and clinical perspective . Journal of Psychopharmacology . 27 . 6 . 479–96 . June 2013 . 23539642 . 10.1177/0269881113482532 . 3666194 .
  45. Web site: King DG . 4 January 2017 . Prescription Forgery . Handwriting Services International . https://web.archive.org/web/20080705185842/http://www.denton.handwritingexperts.com/articles/prescriptionforgery1.html . 5 July 2008 .
  46. Book: Pharmaceutical Manufacturing Encyclopedia . 2nd . Sittig M . 1 . Noyes Publications . 978-0-8155-1144-1.
  47. Web site: Dexedrine FAQs. dead. https://web.archive.org/web/20110617013326/http://www.dexedrine.net/faq.asp. 17 June 2011.
  48. Web site: Bonné J . 'Go pills': A war on drugs? . NBC News . 9 January 2003 . 5 January 2017.
  49. Web site: Woodring JC . Air Force scientists battle aviator fatigue . 5 January 2017 . dead . https://web.archive.org/web/20121014113247/http://www.af.mil/news/story.asp?id=123007615 . 14 October 2012 .
  50. Emonson DL, Vanderbeek RD . The use of amphetamines in U.S. Air Force tactical operations during Desert Shield and Storm . Aviation, Space, and Environmental Medicine . 66 . 3 . 260–3 . 1995 . 7661838 .
  51. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present – a pharmacological and clinical perspective . J. Psychopharmacol. . 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532.
  52. Web site: National Drug Code Amphetamine Search Results . National Drug Code Directory. U.S. Food and Drug Administration (FDA) . 16 December 2013 . https://web.archive.org/web/20131216080856/http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&numberperpage=160&searchfield=amphetamine&searchtype=ActiveIngredient&OrderBy=ProprietaryName . 16 December 2013.
  53. Web site: Mydayis- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate capsule, extended release . DailyMed . 28 October 2022 . 21 January 2023.
  54. Web site: Adzenys XR-ODT- amphetamine tablet, orally disintegrating . DailyMed . 10 March 2022 . 21 January 2023.
  55. Web site: Drug Approval Package: Adzenys XR-ODT (amphetamine) . U.S. Food and Drug Administration (FDA) . 27 January 2016 . 21 January 2023.
  56. Web site: Drug Approval Package: Dyanavel XR . U.S. Food and Drug Administration (FDA) . 21 March 2022 . 21 January 2023.
  57. Web site: Evekeo . U.S. Food and Drug Administration (FDA) . 11 August 2015.
  58. Web site: Zenzedi (dextroamphetamine sulfate, USP) . Zenzedi.com . 5 January 2017.
  59. Web site: ProCentra (dextroamphetamine sulfate 5 mg/5 mL Oral Solution) . FSC Laboratories . https://web.archive.org/web/20101005052859/http://www.fsclabs.com/ProCentra.html . 5 October 2010 .
  60. Mickle T, Krishnan S, Bishop B, Lauderback C, Moncrief JS, Oberlender R, Piccariello T, Paul BJ, Verbicky CD . 2010 . Abuse-resistant amphetamine prodrugs . US . 7655630 . Takeda Pharmaceutical Co Ltd .
  61. 10.18773/austprescr.1995.064 . Stimulant treatment for attention deficit hyperactivity disorder . Australian Prescriber . 18 . 3 . 60–63 . 1995 . Hazell P .
  62. Web site: Pharmaceutical Services . .health.nsw.gov.au . 5 January 2017 . dead . https://web.archive.org/web/20130505045845/http://www0.health.nsw.gov.au/PublicHealth/Pharmaceutical/adhd/faqs.asp . 5 May 2013 .
  63. Web site: Dexamfetamine sulphate - Medicinal forms . British National Formulary . BMJ Group and Pharmaceutical Press (Royal Pharmaceutical Society) . 9 November 2019.
  64. Dexamfetamine – Prescribe Generically . Red/Amber News . 22 . https://web.archive.org/web/20130518094535/http://www.ipnsm.hscni.net/news/RedAmberNewsNov10.pdf . 18 May 2013 . 2 . Interface Pharmacist Network Specialist Medicines (IPNSM) . November 2010 . 20 April 2012 .
  65. Hutson PH, Pennick M, Secker R . Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug . Neuropharmacology . 87 . 41–50 . December 2014 . 24594478 . 10.1016/j.neuropharm.2014.02.014 . 37893582 .
  66. Web site: Elayan I . NRP-104 (lisdexamphetamine dimesylate) . Pharmacology/Toxicology Review and Evaluation . U.S. Food and Drug Administration . 2006 . 18–19 .
  67. Mohammadi M, Akhondzadeh S . Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy . Acta Medica Iranica . 49 . 8 . 487–498 . September 2011 . 22009816 . 12 March 2014 .
  68. Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D . A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil . Neuropharmacology . 73 . 348–358 . October 2013 . 23748096 . 10.1016/j.neuropharm.2013.05.021 . 25343254 .
  69. Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ . Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity . Neuropharmacology . 63 . 6 . 1064–1074 . November 2012 . 22796358 . 10.1016/j.neuropharm.2012.07.008 . 29702399 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dextroamphetamine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.